动物实验,中风,安眠药 z-bo 2020-09-21 322

　　Scientists looking for drugs to help recover from stroke can find the drugs they need in the bedside tables of millions of American families. Compared with the control group who took a placebo, after treatment with a small dose of Ambien (a sleeping pill), the mice recovered from a stroke faster. Ambien is a typical Zolpidem drug. Since 2011, related prescriptions have been prescribed no less than 40 million times in the United States.

　　Researchers said that this finding has been replicated by other laboratories before conducting clinical trials. This finding is very interesting for a difficult disease that requires treatment.

　　Stroke will block the blood supply to part of the brain, causing body tissues to die due to lack of oxygen. After a stroke, some tissues can be repaired within a few months, but most patients will never recover. Although physical therapy has a certain effect, there has been no medicine that can speed up the repair of brain tissue.

　　"There are many natural methods that can improve the routine recovery of animals and humans, but their effects are limited." said Gary Steinberg, a professor at Stanford University School of Medicine and the lead author of the project.

　　One of the mechanisms may be through the increase of GABA neurotransmitter in the brain to transmit signals and reconnect them. Because Ambien can have an effect on GABA receptors, Steinberg and the team are curious whether they can use Ambien's mechanism to improve patient recovery.

　　Researchers introduced two stroke modes in mice, the first mode is impaired in perception and the second mode is impaired in exercise ability. Compared with mice taking placebo, mice taking Ambien (the dose was small enough to make them fall asleep) the tape on their paws moved faster.

　　Steinberg said that more animal experiments are still needed to determine the best dose and best time for the drug. In fact, the US Food and Drug Administration (FDA) has approved that human clinical trials will soon be available. "We are not ready to enter the clinical trial phase, but we are planning."